Maxigen Biotech Inc. reported consolidated revenues results for the month and year to date ended October 2022. On a consolidated basis, revenues for October 2022 were approximately TWD 50.288 million, a decrease of 11.54% over the same period in 2021.

Revenues for January through October 2022 totaled TWD 490.412 million, an increase of 14.72% compared to the TWD 427.498 million for the same period in 2021.